# Durham's Incyclix Bio Raises $52M for Gentler Cancer Therapies

> Incyclix Bio secures $52M to develop less toxic cancer treatments for breast and ovarian cancers.
- Title: Durham's Incyclix Bio Raises $52M for Gentler Cancer Therapies
- Summary: Incyclix Bio secures $52M to develop less toxic cancer treatments for breast and ovarian cancers. Incyclix Bio raised $52 million for precision cancer…
- Keywords: incyclix bio, durham, breast cancer, ovarian cancer, cdk2 inhibitors, clinical trials, precision oncology, startups, business, Durham's, Incyclix, Bio
- Source: Dealroom — https://dealroom.co/news/161524-durhams-incyclix-bio-raises-52m-for-gentler-cancer-therapies
- Published: 2026-10-10T21:54:58+00:00
- Read time: 1 min
- Topics: incyclix bio, durham, breast cancer, ovarian cancer, cdk2 inhibitors, clinical trials, precision oncology, startups, business
## New Funding Round
Durham-based Incyclix Bio raised $52 million in a late-stage venture round to advance precision treatments for breast and ovarian cancers now in clinical trials.
## Drug Development
The biotech, founded in 2020 by Patrick Roberts, Jay Strum, and John Bisi, is developing CDK2 inhibitors to curb tumor growth with fewer side effects than traditional chemotherapy.
## Lead Drug
Its lead drug, INX 315, adds a CDK2 inhibitor on top of existing treatments to overcome resistance that lets cancer return.
## Clinical Trials
INX 315 is in trials across 19 hospitals targeting patients whose breast or ovarian cancer progressed despite earlier CDK4/6 treatment.
## Key takeaway

Incyclix Bio raised $52 million for precision cancer therapies targeting resistance to existing treatments.